H. Lundbeck A/S
HLUN-A
Hisse Senetlerindeki Sıralama
#3028
H. Lundbeck A/S engages in the research, development, manufacturing, and... H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Hisse Fiyatı
$7.24
Piyasa Değeri
$6.03B
Değişim (1 gün)
1.11%
Değişim (1 yıl)
30.63%
Ülke
DK
Ticaret H. Lundbeck A/S (HLUN-A)
Kategori
Healthcare
H. Lundbeck A/S (HLUN-A) için Faaliyet Marjı
October 2026 itibarıyla Faaliyet Marjı TTM: 27.21%
H. Lundbeck A/S şirketinin en son finansal raporlarına ve hisse fiyatına göre, mevcut faaliyet marjı (TTM) 27.21%'dir. 2024 yılı sonunda şirketin faaliyet marjı 14.86% idi.
H. Lundbeck A/S için 2004 ile 2026 arasındaki Faaliyet Marjı geçmişi
Her yıl sonunda Faaliyet Marjı
| Yıl | Faaliyet Marjı | Değiştir |
|---|---|---|
| 2026 (TTM) | 27.21% | 4.45% |
| 2025 | 26.05% | 75.30% |
| 2024 | 14.86% | -7.41% |
| 2023 | 16.05% | 2.69% |
| 2022 | 15.63% | 26.76% |
| 2021 | 12.33% | 9.50% |
| 2020 | 11.26% | -45.84% |
| 2019 | 20.79% | -29.91% |
| 2018 | 29.66% | 15.95% |
| 2017 | 25.58% | 74.49% |
| 2016 | 14.66% | -132.77% |
| 2015 | -44.73% | -6,144.59% |
| 2014 | 0.74% | -92.94% |
| 2013 | 10.48% | -5.84% |
| 2012 | 11.13% | -47.50% |
| 2011 | 21.20% | -6.77% |
| 2010 | 22.74% | 9.38% |
| 2009 | 20.79% | -0.24% |
| 2008 | 20.84% | -15.08% |
| 2007 | 24.54% | 26.82% |
| 2006 | 19.35% | -19.11% |
| 2005 | 23.92% | -8.84% |
| 2004 | 26.24% | 0.00% |
Benzer şirketler veya rakipler için Faaliyet Marjı
| Şirket | Faaliyet Marjı | Faaliyet Marjı Farkı | Ülke |
|---|---|---|---|
| 62.34% | -97.71% |
US
|
|
| 0.00% | - |
SE
|
|
| 0.00% | - |
FR
|
|
| 0.00% | - |
IT
|
|
| 29.76% | -98.91% |
HK
|
Bir şirketin Faaliyet Marjı'ı nedir?
Faaliyet Marjı, bir şirketin kârlılığını değerlendirmek için temel bir göstergedir. Daha yüksek Faaliyet Marjı değerleri genellikle daha iyidir çünkü bir şirketin ürün veya hizmetlerini üretim maliyetlerinden çok daha yüksek bir fiyata satabildiğini gösterir. Faaliyet Marjı, şirketin kârının gelirine bölünmesiyle hesaplanır.